Overview: Remdesivir and long-term outcomes after COVID-19 hospitalization Remdesivir (RDV) has been evaluated for short-term benefits in both hospitalized and non-hospitalized patients with COVID-19. However, its impact on long-term outcomes, particularly for patients who survive the initial hospitalization, has been less clear. A real-world study across three health systems in Colorado and Utah examined whether…